Literature DB >> 18684698

Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.

M R Bishop1, R M Dean, S M Steinberg, J Odom, S Z Pavletic, C Chow, S Pittaluga, C Sportes, N M Hardy, J Gea-Banacloche, A Kolstad, R E Gress, D H Fowler.   

Abstract

BACKGROUND: A graft-versus-lymphoma effect against diffuse large B-cell lymphoma (DLBCL) is inferred by sustained relapse-free survival after allogeneic stem-cell transplantation; however, there are limited data on a direct graft-versus-lymphoma effect against DLBCL following immunotherapeutic intervention by either withdrawal of immunosuppression or donor lymphocyte infusion (DLI).
MATERIALS AND METHODS: An analysis was carried out to determine whether a direct graft-versus-lymphoma effect exists against DLBCL. The analysis was restricted to patients with DLBCL, who were either not in complete remission at day +100 after allogeneic stem-cell transplantation or subsequently relapsed beyond this time point.
RESULTS: Fifteen patients were identified as either not in complete remission (n = 13) at their day +100 evaluation or subsequently relapsed (n = 2) and were assessed for subsequent responses after withdrawal of immunosuppression or DLI. Eleven patients were treated with either withdrawal of immunosuppression (n = 10) or a DLI (n = 1) alone; four patients received chemotherapy with DLI to reduce tumor bulk. Nine (60%) patients subsequently responded (complete = 8, partial = 1). Six responses occurred after withdrawal of immunosuppression alone. Six patients are alive (range 42-83+ months) in complete remission without further treatment.
CONCLUSION: The demonstration of sustained complete remission following immunotherapeutic intervention provides direct evidence of a graft-versus-lymphoma effect against DLBCL.

Entities:  

Mesh:

Year:  2008        PMID: 18684698      PMCID: PMC2733078          DOI: 10.1093/annonc/mdn404

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  29 in total

1.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

2.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

3.  Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect.

Authors:  C S Higano; M Brixey; E M Bryant; D M Durnam; K Doney; K M Sullivan; J W Singer
Journal:  Transplantation       Date:  1990-07       Impact factor: 4.939

4.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

5.  Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  C Haioun; E Lepage; C Gisselbrecht; Y Bastion; B Coiffier; P Brice; A Bosly; B Dupriez; C Nouvel; H Tilly; P Lederlin; P Biron; J Brière; P Gaulard; F Reyes
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 6.  Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology.

Authors:  Andrew Grigg; David Ritchie
Journal:  Biol Blood Marrow Transplant       Date:  2004-09       Impact factor: 5.742

7.  Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.

Authors:  Maricer P Escalón; Richard E Champlin; Rima M Saliba; Sandra A Acholonu; Chitra Hosing; Luis Fayad; Sergio Giralt; Naoto T Ueno; Farzaneh Maadani; Barbara Pro; Michele Donato; Peter McLaughlin; Issa F Khouri
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

8.  Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.

Authors:  V Ratanatharathorn; J Uberti; C Karanes; E Abella; L G Lum; F Momin; G Cummings; L L Sensenbrenner
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

9.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.

Authors:  D L Porter; M S Roth; C McGarigle; J L Ferrara; J H Antin
Journal:  N Engl J Med       Date:  1994-01-13       Impact factor: 91.245

10.  Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.

Authors:  R J Jones; R F Ambinder; S Piantadosi; G W Santos
Journal:  Blood       Date:  1991-02-01       Impact factor: 22.113

View more
  26 in total

1.  Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.

Authors:  A-K Zoellner; S Fritsch; D Prevalsek; N Engel; M Hubmann; R Reibke; C T Rieger; J C Hellmuth; M Haas; F Mumm; T Herold; G Ledderose; W Hiddemann; M Dreyling; A Hausmann; J Tischer
Journal:  Bone Marrow Transplant       Date:  2015-02-02       Impact factor: 5.483

Review 2.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

3.  Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.

Authors:  Timothy S Fenske; Kwang W Ahn; Tara M Graff; Alyssa DiGilio; Qaiser Bashir; Rammurti T Kamble; Ernesto Ayala; Ulrike Bacher; Jonathan E Brammer; Mitchell Cairo; Andy Chen; Yi-Bin Chen; Saurabh Chhabra; Anita D'Souza; Umar Farooq; Cesar Freytes; Siddhartha Ganguly; Mark Hertzberg; David Inwards; Samantha Jaglowski; Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Sunita Nathan; Attaphol Pawarode; Miguel-Angel Perales; Nishitha Reddy; Sachiko Seo; Anna Sureda; Sonali M Smith; Mehdi Hamadani
Journal:  Br J Haematol       Date:  2016-03-15       Impact factor: 6.998

4.  Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Authors:  E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; R Bouadballah; J Radford; M Bargetzi; V Ribrag; U Dührsen; D Ma; J Briere; C Thieblemont; E Bachy; C H Moskowitz; B Glass; C Gisselbrecht
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

5.  Modelling lymphoma therapy and outcome.

Authors:  Katja Roesch; Dirk Hasenclever; Markus Scholz
Journal:  Bull Math Biol       Date:  2013-12-14       Impact factor: 1.758

6.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Authors:  James N Kochenderfer; Mark E Dudley; Robert O Carpenter; Sadik H Kassim; Jeremy J Rose; William G Telford; Frances T Hakim; David C Halverson; Daniel H Fowler; Nancy M Hardy; Anthony R Mato; Dennis D Hickstein; Juan C Gea-Banacloche; Steven Z Pavletic; Claude Sportes; Irina Maric; Steven A Feldman; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R Bishop; Ronald E Gress; Steven A Rosenberg
Journal:  Blood       Date:  2013-09-20       Impact factor: 22.113

Review 7.  Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?

Authors:  M A Kharfan-Dabaja; N El-Jurdi; E Ayala; A S Kanate; B N Savani; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

Review 8.  Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Authors:  Timothy S Fenske; Mehdi Hamadani; Jonathon B Cohen; Luciano J Costa; Brad S Kahl; Andrew M Evens; Paul A Hamlin; Hillard M Lazarus; Effie Petersdorf; Christopher Bredeson
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-27       Impact factor: 5.742

Review 9.  Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?

Authors:  E Klyuchnikov; U Bacher; T Kroll; T C Shea; H M Lazarus; C Bredeson; T S Fenske
Journal:  Bone Marrow Transplant       Date:  2013-05-27       Impact factor: 5.483

10.  Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Authors:  Ulrike Bacher; Evgeny Klyuchnikov; Jennifer Le-Rademacher; Jeanette Carreras; Philippe Armand; Michael R Bishop; Christopher N Bredeson; Mitchell S Cairo; Timothy S Fenske; Cesar O Freytes; Robert Peter Gale; John Gibson; Luis M Isola; David J Inwards; Ginna G Laport; Hillard M Lazarus; Richard T Maziarz; Peter H Wiernik; Harry C Schouten; Shimon Slavin; Sonali M Smith; Julie M Vose; Edmund K Waller; Parameswaran N Hari
Journal:  Blood       Date:  2012-09-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.